30Oct/13

Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome … – 7thSpace Interactive (press release)

Efficacy and safety of rituximab treatment in early primary Sjogren’s syndrome
7thSpace Interactive (press release)
IntroductionPrimary Sjogren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands and characterized, in most cases, by a rather mild clinical picture. However, a subgroup of pSS patients experience systemic extra-glandular involvement 

29Oct/13

Kala-azar bug has become resistant to drug of choice – Times of India

Kala-azar bug has become resistant to drug of choice
Times of India
LONDON: High levels of arsenic contamination in food and drinking water is fuelling one of India’s worst scourges, Visceral Leishmaniasis or Kala-azar, the second largest parasitic killer in the world after malaria with a 90% fatality rate within two
Arsenic in India’s water could cause resistance to visceral leishmaniasis Medical Xpress

all 3 news articles »

29Oct/13

Gilead Sciences, Inc. (GILD): Gilead Sciences' CEO Discusses Q3 2013 Results … – Seeking Alpha

Gilead Sciences, Inc. (GILD): Gilead Sciences’ CEO Discusses Q3 2013 Results
Seeking Alpha
This application was supported by data from Study-10109, a single arm open label Phase 2 study of 125 patients who were refractory to both rituximab and alkylating agent chemotherapy. In this study Idelalisib achieved an overall response rate of 54
Gilead Sciences Announces Third Quarter 2013 Financial ResultsBusiness Wire (press release)

all 15 news articles »